Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  High-risk disease defined by a total Gleason Sum Score greater than equal to (>=) 4+3
             (=Grade Groups [GG] 3 5) and >=1 of the following 4 criteria: a) Any combination of
             Gleason Score 4+3 (= 3) and Gleason Score 8 (4+4 or 5+3) in >= 6 systematic cores
             (with >=1 core Gleason Score 8 [4+4 or 5+3] included); b) Any combination of Gleason
             Score 4+3 (=GG 3) and Gleason Score 8 (4+4 or 5+3) in >=3 systematic cores and
             Prostate-specific antigen (PSA) >=20 ng/mL (with >= 1 core Gleason Score 8 [4+4 or
             5+3] included); c) Gleason Score >=9 (=GG 5) in at least 1 systematic or targeted
             core; d) At least 2 systematic or targeted cores with continuous Gleason Score >=8
             (=GG 4), each with > 80 percent (%) involvement

          -  Candidate for radical prostatectomy with pelvic lymph node dissection as per the
             investigator

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

          -  Contraceptive use by men and female partners of men enrolled in the study who are of
             childbearing potential or are pregnant) should be consistent with local regulations
             regarding the use of contraceptive methods for participants participating in clinical
             studies

          -  Able to receive androgen deprivation therapy (ADT) for at least 13 months

        Exclusion Criteria:

          -  Distant metastasis based on conventional imaging (clinical stage M1). Nodal disease
             below the iliac bifurcation (clinical stage N1) is not an exclusion. Diagnosis of
             distant metastasis (clinical M stage; M0 versus M1a, M1b, M1c) and pelvic nodal
             disease (clinical N stage; N1 versus N0) will be assessed by central radiological
             review. Participants are considered eligible only if the central radiological review
             confirms clinical stage M0

          -  (a) Prior treatment with androgen receptor antagonists; (b) Treatment with
             gonadotropin-releasing hormone analog (GnRHa) prior to informed consent form (ICF)
             signature

          -  History of prior systemic or local therapy for prostate cancer, including pelvic
             radiation for prostate cancer

          -  Use of any investigational agent less than or equals to (<=)4 weeks prior to
             randomization or any therapeutic procedure for prostate cancer at any time

          -  Major surgery <=4 weeks prior to randomization

          -  Any of the following within 12 months prior to first dose of study drug: severe or
             unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial
             or venous thromboembolic events (example, pulmonary embolism, cerebrovascular accident
             including transient ischemic attacks), or clinically significant ventricular
             arrhythmias or New York Heart Association Class II to IV heart disease; uncomplicated
             deep vein thrombosis is not considered exclusionary